Search
Bromazepam
go.drugbank.com/drugs/DB01558ApprovedIllicitOne of the benzodiazepines that is used in the treatment of anxiety disorders. It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. … It is a intermediate-acting benzodiazepine.
Products: BROMAZEPAM N&PBrigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. … It presents selectivity against the mutant forms of EGFR compared to the wild-type.
CYT006-AngQb
go.drugbank.com/drugs/DB05739InvestigationalCYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. … It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure
Foscarnet
go.drugbank.com/drugs/DB00529ApprovedInvestigationalAn antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.
Isopropamide
go.drugbank.com/drugs/DB01625ApprovedVet approvedWithdrawnIsopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.
Entecavir
go.drugbank.com/drugs/DB00442ApprovedInvestigationalIt was approved by the U.S. Food and Drug Administration (FDA) in March 2005. … Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
SIG-001
go.drugbank.com/drugs/DB17826InvestigationalSIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer
Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnLevopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s. … [T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered as a capsule or suspension.
Morniflumate
go.drugbank.com/drugs/DB09285InvestigationalIn one study, post morniflumate ingestion, physical examination and clinical symptoms of those with bronchitis showed improvement [A7889]. … Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid [L1496].